Biotech Values

[pi]

to poorgradstudent on vernakalant --

I respectfully disagree with you. It is true that the studies you have cited favor rate control but the studies do not effectively address morbidity and that is a downstream event that is difficult to ascertain. In addition the ease of use of vernakalent would favor it over cardioversion anyday. And there is indication that rhythm sustainability can be in vernakalant's favor. Now IF the oral form is only half as efficacious with the same safety profile there will be no question what the patient will prefer and what the market will be.